Amgen to Present at 19th Annual Credit Suisse Healthcare Conference

THOUSAND OAKS, Calif., Nov. 9, 2010 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) will participate in the 19th Annual Credit Suisse Healthcare Conference on Friday, Nov. 12, 2010, at the Biltmore Hotel in Phoenix, Ariz., beginning at 8:30 a.m. Mountain Time.  Jonathan M. Peacock, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen's website, www.amgen.com, under Investors.

Information regarding presentation time, webcast availability, and webcast links are available on Amgen's Investor Relations Events Calendar.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics.  A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient.  Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses.  With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.  To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

CONTACT: Amgen, Thousand Oaks

David Polk, 805-447-4613 (media)

Arvind Sood, 805-447-1060 (investors)



(Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20081015/AMGENLOGO)

SOURCE Amgen

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.